MYCN and neuroblastoma: Antigene oligonucleotide therapy by targeting MYCN transcription has been demonstrated by the novel MYCN-specific agPNA BGA002 [152] in the preclinical treatment of neuroblastoma, and has also great potential in treating other aggressive MYCN-expressing tumors.